Doximity Inc. reported total revenues of USD 185.1 million for its fiscal 2026 third quarter (Q3), representing a 10% increase year-over-year. Net income for the period was USD 61.6 million, with a margin of 33%. Adjusted EBITDA reached USD 111.4 million, yielding a margin of 60%. Operating cash flow for the quarter was USD 60.9 million, while free cash flow stood at USD 58.5 million, reflecting decreases of 7% and 8% year-over-year, respectively. During the quarter, Doximity saw record engagement on its platform, with more than 1 million quarterly active prescribers using its newsfeed and 720,000 users of its workflow products, marking a record quarter-on-quarter increase. The company also reported over 300,000 users for its new AI-powered products. Doximity highlighted the impact of AI feature integration in enhancing the platform’s utility for medical professionals. The board of directors authorized a new stock repurchase program for up to USD 500 million of Class A common stock with no expiration date. For its fiscal fourth quarter ending March 31, 2026, Doximity expects revenue between USD 143 million and USD 144 million and adjusted EBITDA between USD 63.5 million and USD 64.5 million. For the full fiscal year ending March 31, 2026, the company updated its guidance to revenue between USD 642.5 million and USD 643.5 million and adjusted EBITDA between USD 355.5 million and USD 356.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Doximity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205969285) on February 05, 2026, and is solely responsible for the information contained therein.